SEC Comment Letter for Silence Therapeutics (SLN) — Jan 9, 2026
Silence Therapeutics plc
Date: Jan. 9, 2026 · CIK: 0001479615 · Accession: 0000000000-26-000315
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39487
Letter
Re: Silence Therapeutics plc Form 10-K fo the fiscal year ended December 31, 2024 File No. 001-39487 Dear Rhonda Hellums:
January 9, 2026
Rhonda Hellums Chief Financial Officer Silence Therapeutics plc 12 Hammersmith Road London, W14 8TH United Kingdom
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 9, 2026 Rhonda Hellums Chief Financial Officer Silence Therapeutics plc 12 Hammersmith Road London, W14 8TH United Kingdom Re: Silence Therapeutics plc Form 10-K fo the fiscal year ended December 31, 2024 File No. 001-39487 Dear Rhonda Hellums: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>